Olmesartan Dosing
The recommended starting dose of olmesartan is 20 mg once daily for most adults, which can be increased to 40 mg once daily after 2 weeks if blood pressure control is inadequate; no dose adjustment is needed for patients over 65 years, but consider starting at a lower dose in patients with moderate renal impairment. 1
Standard Adult Dosing
- Starting dose: 20 mg once daily (monotherapy, non-volume depleted patients)
- Titration: May increase to 40 mg once daily after 2 weeks if further BP reduction needed
- Maximum dose: 40 mg once daily (doses above 40 mg show no additional benefit)
- Frequency: Once-daily dosing is optimal; twice-daily offers no advantage 1
Elderly Patients (≥65 Years)
No routine dose adjustment is required for elderly patients. 1 While pharmacokinetic studies show modest accumulation in the elderly (33% higher AUC, 30% reduction in renal clearance) 1, 2, these increases remain well below concentrations observed with 80 mg doses that were well tolerated in clinical trials 2. The drug has demonstrated consistent efficacy and good tolerability in elderly patients, including those with isolated systolic hypertension 3.
Pharmacokinetic considerations in elderly:
- Steady-state AUC 33% higher than younger adults 1
- Half-life: 12.8 hours (age 65-75) and 16.5 hours (≥75 years) vs 10.6-12.3 hours in younger patients 2
- Despite these changes, dose adjustment is not necessary 2
Moderate Renal Impairment
For patients with moderate renal impairment (creatinine clearance 20-39 mL/min), consider a lower starting dose and close monitoring. 1
Renal dosing specifics:
- Mild impairment (CrCl 40-59 mL/min): No dose adjustment required, though AUC increases up to 39% 2
- Moderate impairment (CrCl 20-39 mL/min): Consider lower starting dose; AUC increases up to 82% 2
- Severe impairment (CrCl <20 mL/min): Maximum dose should not exceed 20 mg daily 4; AUC approximately triples with repeated dosing 1
- Hemodialysis: Not studied 1
Volume-Depleted Patients
For patients with possible intravascular volume depletion (e.g., diuretic-treated patients, particularly with impaired renal function), initiate under close medical supervision and consider a lower starting dose. 1 This is critical to avoid hypotension.
Hepatic Impairment
For moderate hepatic impairment (Child-Pugh score 7-9), maximum dose should not exceed 20 mg daily. 4 AUC increases by 48% in moderate hepatic impairment, though Cmax remains similar to healthy subjects 2. Compensatory renal excretion increases with hepatic dysfunction 2.
Clinical Pearls
- Steady state: Achieved within 3-5 days with no accumulation on once-daily dosing 1
- Food effect: None; may be administered with or without food 1
- Dose-response: The drug demonstrates clear dose-dependent efficacy, with 40 mg significantly more effective than 20 mg (p<0.01) 5
- Uptitration benefits: Dose titration from 20 to 40 mg results in clinically meaningful additional BP reductions and higher goal attainment rates 5
Important Caveat
Avoid colesevelam co-administration: When given simultaneously, colesevelam reduces olmesartan Cmax by 28% and AUC by 39%. If both drugs are needed, administer olmesartan 4 hours before colesevelam (reduces interaction to 4% and 15% reductions respectively) 1.